Post-translational peptide splicing and T cell responses.

Mishto, M.; Liepe, J.

doi:10.1016/j.it.2017.07.011

Item

ITEM ACTIONSEXPORT

Add to Basket

Please note that a newer version of this item is available:
https://pure.mpg.de/pubman/item/item_2472896_4

DetailsSummary

Released

Journal Article

Post-translational peptide splicing and T cell responses.

MPS-Authors

/persons/resource/persons208298

Liepe, J.
Research Group of Quantitative and System Biology, MPI for Biophysical Chemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Mishto, M., & Liepe, J. (2017). Post-translational peptide splicing and T cell responses. Trends in Immunology, (in press). doi:10.1016/j.it.2017.07.011.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002D-CF32-1

Abstract

CD8+ T cell specificity depends on the recognition of MHC class I-epitope complexes at the cell surface. These epitopes are mainly produced via degradation of proteins by the proteasome, generating fragments of the original sequence. However, it is now clear that proteasomes can produce a significant portion of epitopes by reshuffling the antigen sequence, thus expanding the potential antigenic repertoire. MHC class I-restricted spliced epitopes have been described in tumors and infections, suggesting an unpredicted relevance of these peculiar peptides. We review current knowledge about proteasome-catalyzed peptide splicing (PCPS), the emerging rules governing this process, and the potential implications for our understanding and therapeutic use of CD8+ T cells, as well as mechanisms generating other non-canonical antigenic epitopes targeted by the T cell response.